Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps coprotheres)

Emmanuel Oluwasegun Adawaren\textsuperscript{a,⁎}, Lillian Mukandiwa\textsuperscript{a,b}, John Chipangura\textsuperscript{b}, Kerri Wolter\textsuperscript{b}, Vinny Naidoo\textsuperscript{a,b}

\textsuperscript{a} Department of Paraclinical Science, Faculty of Veterinary Science, University of Pretoria, South Africa
\textsuperscript{b} Biomedical Research Centre, Faculty of Veterinary Science, University of Pretoria, South Africa

**ABSTRACT**

Asian Gyps vulture species are gradually recovering from the devastating effect of diclofenac being present in contaminated carcasses. This drug was responsible for the death of over 10 million vultures in India, Nepal and Pakistan. To prevent the extinction of vultures, meloxicam was introduced after the ban of veterinary diclofenac. Meloxicam’s safety in vultures was attributed to its short elimination half-life in contrast with diclofenac. The reason for the rapid elimination of meloxicam is yet to be explained. The aim of this study was to evaluate the role of biotransformation in the elimination of meloxicam. Six Cape griffon vultures (Gyps coprotheres) were treated with 2 mg/kg meloxicam intramuscularly for faecal and plasma quantification of meloxicam concentration over time. In the plasma meloxicam was characterised by a half-life, mean residence time, clearance and volume of distribution at steady state of 0.37 ± 0.10 h, 0.90 ± 0.12 h, 0.02 ± 0.001/l/kg and 0.02 ± 0.001/kg respectively (presented as geometric mean). Over the 24 h monitoring period, the total non-metabolised meloxicam in the faeces was 1.35 ± 0.71% of the total concentration in the plasma. Based on the short meloxicam elimination half-life and low cumulative concentration of total faecal meloxicam over a period in excess of 10 half-lives, this study indicates that Cape griffon vultures are efficient metaboliser of meloxicam, which is suggestive of different set of cytochrome enzymes being involved in the metabolism to that for diclofenac in this species. Identification of orthologous human CYP2C9 and CYP3A4 enzyme families in vultures will be an important further step in explaining the differences in the metabolic pathway(s) of meloxicam and diclofenac for the species.

**1. Introduction**

In 2004 Oaks et al., established that three species of Asian Gyps vultures (Gyps indicus, Gyps tenuirostris and Gyps bengalensis) were extremely susceptible to the effects of diclofenac [(2-[2-(6,8-dichloroanilino)] phenyl-acetic acid)] to such an extent that the drug killed nearly 99% of the population (Oaks et al., 2004; Green et al., 2004; Swan et al., 2006b). In order to prevent the extinction of these endangered species of birds, diclofenac was banned in 2006 by the government of the affected countries and the safe alternate meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide], also a non-steroidal anti-inflammatory drug (NSAID), was advocated (Swan et al., 2006a). The advocacy of meloxicam as a safe alternative was based on an extensive safety study, where the absence of apparent ill effect of the drug administered to 35 White-backed (Gyps africanus) vultures, another species susceptible to diclofenac, was demonstrated in birds under both captive and wild conditions. For these studies the estimated likely maximum levels of exposure (MLE) (1.83 mg/kg) was converted to a drug dose of 2 mg/kg, and administered by oral gavage with no clinical sign of renal toxicity or elevated plasma uric acid. The safety of meloxicam as residues was also subsequently demonstrated by feeding birds meat harvested from cattle slaughtered a short period after being treated with meloxicam at 1 mg/kg for five days (twice the recommended dose). The safety of meloxicam has since been demonstrated in the G. bengalensis, G. indicus and G. coprotheres (Swan et al., 2006a). As a result of the advocacy on the use of meloxicam and the concurrent ban on the sale of diclofenac for veterinary use, the previous rate of decline has been slowed with the population finally showing a small degree of recovery (Cuthbert et al., 2011; Cuthbert et al., 2016). For example in Pakistan, there was an increase vulture nesting sites from 11 observed during a survey conducted between 2010 and 2011 to 34 between 2011 and 2014 (Murn...
et al., 2015). While the use of meloxicam was a major contributor in mitigating the rate of declines in vulture numbers, the reason for meloxicam's safety and diclofenac's toxicity remains unknown, especially with both drugs meant to work through the same physiological mechanism. In one explanation, it was suggested that the drug's pharmacokinetics and related species specific metabolism was the important determinant in toxicity, with zero order metabolism being a feature in toxicity (Naidoo et al., 2010). From in vivo studies in the Cape griffon vulture (Gyps coprotheres), meloxicam had a short elimination half-life of 0.50 h in comparison to diclofenac with a half-life of 12.24 h (Naidoo et al., 2008; Naidoo et al., 2009). The role of the half-life in toxicity was also very evident in studies with ketoprofen [2-(3-Benzoylphenyl) propanoic acid] and carprofen [2-(6-Chloro-9H-carbazol-2-yl) propanoic acid] in which deaths were only recorded in Gyps vultures with longer half-life of elimination of 7.37 and 37.75 h for ketoprofen and carprofen respectively. While those who survived had elimination half-lives of 3.24 and 13.99 h for ketoprofen and carprofen (Naidoo et al., 2017b; Naidoo et al., 2010).

The metabolism of the NSAIDs is also markedly different to that reported in man and other mammalian species in that meloxicam is the slowest metabolised in these other species while being rapidly metabolised in the vulture (Naidoo et al., 2008; Engelhardt, 1996; Hasan et al., 2005; Ishizaki et al., 1980). The difference in the metabolism of the different NSAIDs presents an unexpected finding, since the NSAIDs should be metabolised by the same or similar CYP450 enzymes. This tendency to suggest that either different CYP enzymes are responsible for the metabolism of the different NSAIDs like meloxicam and diclofenac in birds versus mammals, or possibly that meloxicam is excreted unchanged i.e. rapid plasma clearance can be indicative of metabolism or rapid excretion of the primary drug. This concept is not too different from evidence available thus far, as meloxicam is general well excreted as one of two major metabolites (i.e. 5’-hydroxymethyl metabolite and 5’-carboxyl metabolite) in the rat, mice, mini-pig, baboon and dog (Busch et al., 1998) in support of metabolic similarity, while in the cat where the drug undergoes hepatic excretion as 50% unchanged drug supports rapid elimination as unmetabolised drug (Grudé et al., 2010). For this study we attempt to obtain a better understanding for the rapid plasma clearance of meloxicam in the vulture, using the Cape griffon vulture (Gyps coprotheres), as the test species. To achieve this, we studied the total concentration of drug in the plasma over a ten hour period as well as the total amount of unchanged meloxicam in the faeces over a 24 h period.

2. Materials and methods

2.1. Materials

Meloxicam (Petcam, Ceva Animal Health, South Africa), HPLC grade acetonitrile (Merck, Darmstadt, GE), 5 ml syringe and needle, 2 ml Eppendorf tube, 5 ml screw capped glass tube, nitrogen gas was obtained from Afrox (Johannesburg, South Africa). Equipment comprised of a vacuum water bath, Beckman Allegra TM FX-22R centrifuge (Beckman Coulter, Palo Alto, CA, USA), and a Beckman System Gold high performance liquid chromatograph (HPLC), equipped with a 126 Solvent Module, a 168 PDA detector, a 508 autosampler, and 32 Karat 8.0 software (Beckman Coulter, Fullerton, CA, USA). Chromatographic separation was achieved with a Thermo Scientific BDS HYPERSIL C18 HPLC column (Thermo Scientific, Runcorn, UK), dimensions: 250 mm × 4.6 mm × 5 μm.

2.2. Animals and experimental protocol

The study was approved by the Animal Ethics Committee (AEC) of the University of Pretoria, South Africa, with project number V014-17. Cape Griffon vultures (n = 6), all non-releasable, were sourced from VulPro conservative centre. All birds used in this study were in captivity for at least one year prior to inclusion in the study. For the study the birds were transferred and housed within the University of Pretoria Biomedical Research Centre (UPBRC) avianes in individual metal cages (1.87 m high × 88 cm wide × 82 cm depth). The cages were spaced to allow for proper ventilation and each bird marked to allow for unique identification and observation. Each cage was provided with a urine pan for easy collection of excreta. The birds were at all times in visual contact with the rest of the birds recruited into the study. The vultures were fed twice weekly with 1 kg of beef each, bought from a commercial butchery and water ad libitum. The birds were returned to VulPro at the end of the study.

For the method validation 25 mg of faeces (the solid and white urine components homogenised) were transferred into 5 ml tube and spiked with 100 μl of meloxicam standard concentration ranging from 3.125–100 μg/ml in triplicate. The spiked excreta sample was homogenised using 1000 μl of acetonitrile using a manual homogenizer. The homogenate was transferred into 2 ml Eppendorf tube and centrifuged at 10,000 rpm for 10 min at 4 °C. After centrifugation, the supernatant was transferred into a clean glass tube and evaporated to dryness at 60 °C under nitrogen. 30 μl of the sample was injected onto the HPLC column, using the same method and equipment as above, with the exception that the mobile phase consisted of a ratio of 50 (A):50 (B), at a flow rate of 1000 μl/min with a total runtime of 12 min and a detection wavelength of 360 nm (Emara et al., 2016). Validation of the method was carried out by a calibration standard curve of meloxicam spiked vulture plasma ranging from 3.125–100 μg/ml in triplicate.
and the dried residue reconstituted with 200 μl of mobile at the mixture ratio as described above for meloxicam standard. Also, 30 μl of the reconstituted sample was injected onto the HPLC column. To ensure the correct identification of the meloxicam peak from the metabolites, a process of standard addition was undertaken for a few samples at a concentration of 25, 50 and 100 μg/ml. The meloxicam peak was confirmed on chromatogram by the increasing absorbance relative to concentration (results not shown). Only after the latter confirmation, were the actual sample analysed for their meloxicam concentration. On chromatogram, the metabolites were identified based on their retention time of 4.72 and 2.68 for 5’-hydroxymethyl and the unknown hydroxyl-metabolite, based on the previous chromatograms published of 3.8 and 2.9 min for 5’-hydroxymethyl and 5’ unknown hydroxyl-metabolite respectively (Naidoo et al., 2008).

2.4. Pharmacokinetic analysis

All pharmacokinetic parameters were calculated with Kinetica 5.0 (Thermo) using a non-compartmental model. The maximum plasma concentration (Cmax) and the time to maximum concentration (Tmax) were read directly from the concentration versus time plasma profile. The area under curve to the last time point (AUClast) and the area under curve were determined using the linear trapezoidal rule. The lower limit of detection (LLOD) of 0.049 μg/ml and the lower limit of quantification (LLOQ) was 0.391 μg/ml. The coefficient of determination (r2) above 0.99 for three independent curves. The lower limit of detection (LLOQ) was 0.098 μg/ml.

The area under curve extrapolated to infinity (AUCtot) was calculated as AUCtot = AUClast + C Last/λ; Vz = Cl/F and MRT = AUMCtot/AUCtot. Pharmacokinetic parameters were described by standard descriptive statistics. The percentage of meloxicam excreted 24 h post dosing was calculated as % E = Sum of total meloxicam (mg) in faeces divided by plasma AUClast multiple by 100. The faecal half-life of meloxicam was calculated as Ln2 divided by slope of linear cumulative curve after 24 h post meloxicam administration.

3. Results

3.1. HPLC validation

For the spiked faecal samples the method was linear from 3.125–100 μg/ml, with the co-efficient of determination (r2) above 0.99 for three independent curves. The lower limit of detection (LLOD) of 0.195 μg/ml and the lower limit of quantification (LLOQ) was 0.098 μg/ml. The coefficient of variation, percentage recovery of meloxicam for the two matrices are presented in Table 1. Both the 5’-hydroxymethyl and the unidentified hydroxyl-metabolites were evident in the faeces.

3.2. Plasma and hepato-renal pharmacokinetics of meloxicam

The plasma pharmacokinetic parameters obtained by non-compartmental analysis are presented in Table 2, and the plasma concentration versus time profile is shown in Fig. 2. All results are presented as geometric mean. The total plasma concentration (Cmax) was 92.79 ± 7.96 μg/ml of meloxicam administered at 2 mg/kg body weight was achieved at 0.56 ± 0.08 h (Tmax). The elimination half-life was 0.37 ± 0.10 h with a mean residence time of 0.90 ± 0.12 h. The total plasma clearance was 0.02 ± 0.00 l/h/kg and the steady state volume of distribution of 0.02 ± 0.00 l/kg. The hepato-renal pharmacokinetic parameters are presented in Table 3 and the hepato-renal concentration versus time curve is shown in Fig. 3. Since birds don’t have a urinary bladder the urinary excretory half-life could not be calculated. As a surrogate the hepato-renal excretory half-life was estimated at 3.78 ± 3.02 h with 1.35 ± 0.71% excretion of the parent drug being present in the total pooled excreted faeces over the 24 h study period. In all cases, it appeared that excretion was complete after 24 h, with no further increase in hepato-renal meloxicam concentration being evident at the 24 h collection point.

4. Discussions

In the recent past, the extreme environmental toxic effect of diclofenac in vultures was mitigated in part by the introduction of meloxicam for use in cattle on the Indian subcontinent (Swan et al., 2006a). Despite the drugs being NSAIDs, the two drugs in vultures are not only distinguished by their marked differences in their safety profiles, but also their half-life of elimination (12.24 ± 0.99 and 0.5 ± 0.00 h for diclofenac and meloxicam respectively) (Naidoo et al., 2008; Naidoo et al., 2010; Naidoo et al., 2017a, 2017b). Surprisingly this is completely opposite to what happens in mammalian species whereby meloxicam tends to have a longer elimination half-life than other NSAIDs. For example, the following elimination half-life of meloxicam have been observed in mice (6.41 h), rat (13.4 h), dog (24 h), pig (121 h), baboon (6.12 h) and human (13.7 h) (Hasan et al., 2005; Ishizaki et al., 1980; Busch et al., 1998). While diclofenac has the following half-life in human (1.5 h), dog (1.3 h), mice (2 h), rat (8.2 h), pig (2.4 h) and baboon (3 h) (Small, 1989; Dutta et al., 2008; Torres-Lopez et al., 1997; Tsuchiya et al., 1980; Oberle et al., 1994; Faige et al., 1988). For meloxicam to have a rapid elimination in complete contrast to the other NSAIDs for the same species, we speculate this may be as a result of the elimination of the non-metabolised drug into the gastro-intestinal tract. For this study, we establish the reason behind the rapid half-life of elimination of meloxicam in the vultures, using the Cape vulture as our

<table>
<thead>
<tr>
<th>Validation time</th>
<th>Faecal spiked sample (µg/ml)</th>
<th>Calculated concentration (µg/ml)</th>
<th>CV %</th>
<th>Recovery %</th>
<th>Plasma spiked sample (µg/ml)</th>
<th>Calculated concentration (µg/ml)</th>
<th>CV %</th>
<th>Recovery %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-day</td>
<td>3.125</td>
<td>3.19</td>
<td>4.82</td>
<td>102.10</td>
<td>3.125</td>
<td>3.09</td>
<td>12.65</td>
<td>98.86</td>
</tr>
<tr>
<td></td>
<td>12.5</td>
<td>12.38</td>
<td>2.37</td>
<td>99.02</td>
<td>6.25</td>
<td>6.55</td>
<td>9.99</td>
<td>104.83</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>22.57</td>
<td>12.23</td>
<td>90.26</td>
<td>12.5</td>
<td>12.69</td>
<td>0.59</td>
<td>101.51</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>47.84</td>
<td>3.00</td>
<td>95.67</td>
<td>25</td>
<td>27.18</td>
<td>3.48</td>
<td>108.72</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>101.70</td>
<td>1.05</td>
<td>101.70</td>
<td>50</td>
<td>49.26</td>
<td>2.47</td>
<td>98.58</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td>101.46</td>
<td>1.45</td>
<td>101.46</td>
</tr>
<tr>
<td>Inter-day</td>
<td>3.125</td>
<td>3.52</td>
<td>8.01</td>
<td>112.49</td>
<td>3.125</td>
<td>3.06</td>
<td>1.13</td>
<td>99.0</td>
</tr>
<tr>
<td></td>
<td>12.5</td>
<td>13.50</td>
<td>9.04</td>
<td>108.03</td>
<td>6.25</td>
<td>6.47</td>
<td>1.84</td>
<td>103.48</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>25.67</td>
<td>12.22</td>
<td>102.68</td>
<td>12.5</td>
<td>12.50</td>
<td>2.13</td>
<td>100.0</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>49.90</td>
<td>3.80</td>
<td>99.81</td>
<td>25</td>
<td>26.24</td>
<td>5.06</td>
<td>104.96</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>99.66</td>
<td>2.00</td>
<td>99.66</td>
<td>50</td>
<td>49.53</td>
<td>0.75</td>
<td>99.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td>100.76</td>
<td>0.99</td>
<td>100.76</td>
</tr>
</tbody>
</table>

Table 1: Accuracy and precision of meloxicam in the faeces and plasma samples.
lower than the other vultures, once again indicating that intra-in- 
travenous administration results in rapid and complete absorption of the drug after 10 half-lives, it is extremely unlikely that any meloxicam would still be present within a bird when they feed again two to three days later. Based on the latter scenario and the known complete elimination of meloxicam in the Cape griffon vultures, and will explain why birds were protected from the exposure dose of 2 mg/kg in initial toxicity studies.

The short elimination half-life of meloxicam will also explain the environmental safety of the drug, as the drug is unlikely to have a cumulative effect. We based on a combination of pharmacokinetic features of meloxicam and behavioural habits of the birds. From a pharmacokinetic point using the longest half-life of 53 min, a bird would need to be exposed to a dose of 2 mg/kg every hour for a cumulative effect. The latter is a physiological impossibility, as the 2 mg/kg exposure dose was extrapolated from the worst case scenario of the bird consuming 1 kg of meat at meal. Further to this, at this level of feeding and basal metabolic needs of the birds (Swan et al., 2006a, 2006b), the bird is only likely to take in such a high dose every second to third day. Based on the latter scenario and the known complete elimination of drug after 10 half-lives, it extremely unlikely that any meloxicam would still be present within a bird when they feed again two to three days later.

An interesting finding in this study was the relatively long hepatorenal excretory half-life of 3.78 h in comparison to the plasma elimination half-life of 0.37 h. We believe that this may be indicative of the route of elimination, with route of elimination being dependent on the molecular weight (MW) of the drug (Toutain et al., 2010). For instance, drug molecules with MW less than 250 are excreted through the renal route while those greater than 300 to 600 are preferably excreted via the biliary route. Variation in the MW range of drug molecules is responsible for interspecies differences with the phenotypic grouping of animals as poor (rabbit, guinea pig, man), good (rats, chickens, dogs) and intermediate biliary excreters (Toutain et al., 2010). For meloxicam with a MW of 351.395 g/mol coupled with species preferences, the biliary route would likely be the preferred route of elimination of non-metabolised meloxicam in the Cape griffon vulture. In addition, birds unlike mammals do not possess a urinary bladder or urethras. The cloaca represents an embryological precursor of the bladder (cysto- deum, urodeum and proctodeum), with the result that urinary clearance is much faster, since there is no urinary retention. The longer

indicator species, by evaluating the percentage of parent meloxicam excreted unchanged in the faeces of the vultures, since birds don’t readily produce a separate urine and faecal fraction.

Following the intramuscular administration of meloxicam to six adult Cape vultures, meloxicam took on average 0.56 h to reach the maximum plasma concentration of 92.79 μg/ml. The maximum plasma concentration of meloxicam in the faeces of every bird sampled. The cumulative excretion of meloxicam showed that meloxicam was 1.35 ± 0.71% of the exposure dose was extrapolated from the worst case scenario of the bird consuming 1 kg of meat at meal. Further to this, at this level of feeding and basal metabolic needs of the birds (Swan et al., 2006a, 2006b), the bird is only likely to take in such a high dose every second to third day. Based on the latter scenario and the known complete elimination of drug after 10 half-lives, it extremely unlikely that any meloxicam would still be present within a bird when they feed again two to three days later.

An interesting finding in this study was the relatively long hepatorenal excretory half-life of 3.78 h in comparison to the plasma elimination half-life of 0.37 h. We believe that this may be indicative of the route of elimination, with route of elimination being dependent on the molecular weight (MW) of the drug (Toutain et al., 2010). For instance, drug molecules with MW less than 250 are excreted through the renal route while those greater than 300 to 600 are preferably excreted via the biliary route. Variation in the MW range of drug molecules is responsible for interspecies differences with the phenotypic grouping of animals as poor (rabbit, guinea pig, man), good (rats, chickens, dogs) and intermediate biliary excreters (Toutain et al., 2010). For meloxicam with a MW of 351.395 g/mol coupled with species preferences, the biliary route would likely be the preferred route of elimination of non-metabolised meloxicam in the Cape griffon vulture. In addition, birds unlike mammals do not possess a urinary bladder or urethras. The cloaca represents an embryological precursor of the bladder (cystodeum, urodeum and proctodeum), with the result that urinary clearance is much faster, since there is no urinary retention. The longer

result was not too dissimilar to other mammalian species reported to excrete non-metabolised meloxicam via renal and biliary routes for mice (0.2%), mini-pig (1%) and baboon (4%) over a 24 h period (Busch et al., 1998). This low cumulative excretion of parent meloxicam would thus indicate that in addition to been rapidly cleared from the plasma, meloxicam is rapidly and fairly completely metabolised in the vulture. The latter would thus rule out the excretion of non-metabolised meloxicam as the reason for the rapid elimination of the drug in the Cape griffon vultures, and will explain why birds were protected from the exposure dose of 2 mg/kg in initial toxicity studies.

The short elimination half-life of meloxicam will also explain the environmental safety of the drug, as the drug is unlikely to have a cumulative effect. We based on a combination of pharmacokinetic features of meloxicam and behavioural habits of the birds. From a pharmacokinetic point using the longest half-life of 53 min, a bird would need to be exposed to a dose of 2 mg/kg every hour for a cumulative effect. The latter is a physiological impossibility, as the 2 mg/kg exposure dose was extrapolated from the worst case scenario of the bird consuming 1 kg of meat at meal. Further to this, at this level of feeding and basal metabolic needs of the birds (Swan et al., 2006a, 2006b), the bird is only likely to take in such a high dose every second to third day. Based on the latter scenario and the known complete elimination of drug after 10 half-lives, it extremely unlikely that any meloxicam would still be present within a bird when they feed again two to three days later.

An interesting finding in this study was the relatively long hepatorenal excretory half-life of 3.78 h in comparison to the plasma elimination half-life of 0.37 h. We believe that this may be indicative of the route of elimination, with route of elimination being dependent on the molecular weight (MW) of the drug (Toutain et al., 2010). For instance, drug molecules with MW less than 250 are excreted through the renal route while those greater than 300 to 600 are preferably excreted via the biliary route. Variation in the MW range of drug molecules is responsible for interspecies differences with the phenotypic grouping of animals as poor (rabbit, guinea pig, man), good (rats, chickens, dogs) and intermediate biliary excreters (Toutain et al., 2010). For meloxicam with a MW of 351.395 g/mol coupled with species preferences, the biliary route would likely be the preferred route of elimination of non-metabolised meloxicam in the Cape griffon vulture. In addition, birds unlike mammals do not possess a urinary bladder or urethras. The cloaca represents an embryological precursor of the bladder (cystodeum, urodeum and proctodeum), with the result that urinary clearance is much faster, since there is no urinary retention. The longer
meloxicam, no e

demonstrable in persons with decreased CYP2C9

system.

reported was still only 40% metabolism (Chesne et al., 1998) ()

Even in people with higher CYP3A4 to CYP2C9 ratios, the maximum
humans, have been shown that CYP2C9 has a lower
as the alternative pathway (Chesne et al., 1998). Ex vivo studies in
bolites present, half-life of elimination, enzymatic pathways described
further delays in excretory times (Duke et al., 1995).

While the enzyme driving the metabolism remains unknown, we
offer the following suggested metabolic pathway based on the meta-
bolites present, half-life of elimination, enzymatic pathways described
in other species, and by contrasting the half-life of diclofenac and
meloxicam. Firstly the presence of the two hydroxyl-metabolites iden-
tified in this study (Fig. 1) indicates cytochrome metabolism as a phase
1 reaction. From human physiology, meloxicam is known to be meta-
bolised by the CYP2C9 enzymes in metabolically competent people
(Bort et al., 1999; Sanoh et al., 2012; Kumar et al., 2002; Yasar et al.,
2001; Chesne et al., 1998), and to a somewhat lower extent by CYP3A4
as the alternative pathway (Chesne et al., 1998). Ex vivo studies in
humans, have been shown that CYP2C9 has a lower $K_m$ value than
CYP3A4 for meloxicam, with the latter contributing only slightly to the
metabolism even though it is found at a higher content in the liver.
Even in people with higher CYP3A4 to CYP2C9 ratios, the maximum
reported was still only 40% metabolism (Chesne et al., 1998) ().

Nonetheless the CYP3A4 system is adaptable and can become a primary
metabolic pathway as demonstrable in persons with decreased CYP2C9
activity in whom it has been demonstrated that the pharmacokinetics
of meloxicam is not compromised (Chesne et al., 1998). In contrast to
meloxicam, no effective alternative metabolic pathway appears to be
present for diclofenac, with CYP2C9 being the only important enzyme
system.

hepato-renal half-life would thus be indicative of hepatic clearance of
the drug via the bile, as the longer transit time would correspond to
gastric transit. Another important mechanism that could also delay
excretion in whom it has been demonstrated that the pharmacokinetics of
metabolic pathway as demonstrable in persons with decreased CYP2C9

1 reaction. From human physiology, meloxicam is known to be meta-
bolised by the CYP2C9 enzymes in metabolically competent people
(Bort et al., 1999; Sanoh et al., 2012; Kumar et al., 2002; Yasar et al.,
2001; Chesne et al., 1998), and to a somewhat lower extent by CYP3A4
as the alternative pathway (Chesne et al., 1998). Ex vivo studies in
humans, have been shown that CYP2C9 has a lower $K_m$ value than
CYP3A4 for meloxicam, with the latter contributing only slightly to the
metabolism even though it is found at a higher content in the liver.
Even in people with higher CYP3A4 to CYP2C9 ratios, the maximum
reported was still only 40% metabolism (Chesne et al., 1998) ().

Nonetheless the CYP3A4 system is adaptable and can become a primary
metabolic pathway as demonstrable in persons with decreased CYP2C9
activity in whom it has been demonstrated that the pharmacokinetics
of meloxicam is not compromised (Chesne et al., 1998). In contrast to
meloxicam, no effective alternative metabolic pathway appears to be
present for diclofenac, with CYP2C9 being the only important enzyme
system.

Based on the long half-life of diclofenac we speculate that the vul-
ture has to be de

Fig. 1. Chromatogram of meloxicam (MLX) 5’-hydroxymethyl metabolite (a) and unidentified hydroxy-metabolite (b) from the faecal (A) and plasma sample (B).

Fig. 2. Mean plasma concentration vs time curve following intramuscular meloxicam administration in adult Gyps coprotheres vultures.

Fig. 3. Mean cumulative hepato-renal concentration vs time curve on the log scale following intramuscular meloxicam administration in adult Gyps coprotheres vultures (Error bars are presented as SEM).

The presences of multiple CYP2C enzymes in the metabolism of
meloxicam is not an unusual finding and has been previously described
in the rat with CYP2C11 and CYP2C7 involved in the metabolism of
meloxicam (Schmid et al., 1995; Martignoni et al., 2006). Further,
support for an additional CYP2C enzymes being involved in metabolism
is the second unknown hydroxy metabolite found in the faeces (Fig. 1).
To our knowledge the only other time that other hydroxy metabolites of meloxicam have been identified has been in the Koala (Phascolarctos cinereus) where two unknown hydroxy metabolites were identified (Kimble et al., 2013), in conjunction with a rapid half-life of 1.2 h (Kimble et al., 2013). They also speculated that other CYP enzymes isoforms must be involved in the metabolism of meloxicam, which may be an adaptive mechanism to the diet of the Koalas and a means of conserving energy. The latter would make sense for the vulture, which as the species is adapted to a scavenging life-style that necessitates minimisation of energy requirements (Komen, 1992). Unfortunately at this point, we are unsure which enzymes may be, but speculate that it has to be one of the two CYP2C9 analogues mentioned above.

5. Conclusion

In conclusion, the study shows that the safety of meloxicam in old world vultures is due to the rapid metabolism of meloxicam and not the primary excretion of parent meloxicam as evident in the cat. While speculative we believe this is highly indicative of different pathways in the metabolism of diclofenac and meloxicam in the vulture to that of mammals. It is therefore important to further investigate the orthologous CYP2C and CYP3A enzyme families in order to obtain a further understanding of the metabolism of meloxicam and diclofenac in vultures.

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgement

This research was funded by the National Research Foundation (NRF) of South Africa (Grant no 87772). Furthermore, we kindly extend our profound gratitude to Mrs. Kerri Wolter and the entire VUlPro technical team for providing the birds as well as technical support in handling procedure throughout the entire period of the research. We also want to acknowledge the contribution of technical staff in the section of pharmacology and pathology at the Faculty of Veterinary Science for their invaluable support in making the project a success.

References


To our knowledge the only other time that other hydroxy metabolites of meloxicam have been identified has been in the Koala (Phascolarctos cinereus) where two unknown hydroxy metabolites were identified (Kimble et al., 2013), in conjunction with a rapid half-life of 1.2 h (Kimble et al., 2013). They also speculated that other CYP enzymes isoforms must be involved in the metabolism of meloxicam, which may be an adaptive mechanism to the diet of the Koalas and a means of conserving energy. The latter would make sense for the vulture, which as the species is adapted to a scavenging life-style that necessitates minimisation of energy requirements (Komen, 1992). Unfortunately at this point, we are unsure which enzymes may be, but speculate that it has to be one of the two CYP2C9 analogues mentioned above.

5. Conclusion

In conclusion, the study shows that the safety of meloxicam in old world vultures is due to the rapid metabolism of meloxicam and not the primary excretion of parent meloxicam as evident in the cat. While speculative we believe this is highly indicative of different pathways in the metabolism of diclofenac and meloxicam in the vulture to that of mammals. It is therefore important to further investigate the orthologous CYP2C and CYP3A enzyme families in order to obtain a further understanding of the metabolism of meloxicam and diclofenac in vultures.

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgement

This research was funded by the National Research Foundation (NRF) of South Africa (Grant no 87772). Furthermore, we kindly extend our profound gratitude to Mrs. Kerri Wolter and the entire VUlPro technical team for providing the birds as well as technical support in handling procedure throughout the entire period of the research. We also want to acknowledge the contribution of technical staff in the section of pharmacology and pathology at the Faculty of Veterinary Science for their invaluable support in making the project a success.

References